These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 16984739)

  • 21. No beneficial effects of pine bark extract on cardiovascular disease risk factors.
    Drieling RL; Gardner CD; Ma J; Ahn DK; Stafford RS
    Arch Intern Med; 2010 Sep; 170(17):1541-7. PubMed ID: 20876405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
    Salehi B; Imani R; Mohammadi MR; Fallah J; Mohammadi M; Ghanizadeh A; Tasviechi AA; Vossoughi A; Rezazadeh SA; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):76-80. PubMed ID: 19815048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of treatment of diabetic rats with combinations of pycnogenol, beta-carotene, and alpha-lipoic acid on parameters of oxidative stress.
    Berryman AM; Maritim AC; Sanders RA; Watkins JB
    J Biochem Mol Toxicol; 2004; 18(6):345-52. PubMed ID: 15674846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pycnogenol® improvements in asthma management.
    Belcaro G; Luzzi R; Cesinaro Di Rocco P; Cesarone MR; Dugall M; Feragalli B; Errichi BM; Ippolito E; Grossi MG; Hosoi M; Errichi S; Cornelli U; Ledda A; Gizzi G
    Panminerva Med; 2011 Sep; 53(3 Suppl 1):57-64. PubMed ID: 22108478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oligomeric procyanidins of French maritime pine bark extract (Pycnogenol) effectively inhibit alpha-glucosidase.
    Schäfer A; Högger P
    Diabetes Res Clin Pract; 2007 Jul; 77(1):41-6. PubMed ID: 17098323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attention Deficit Hyperactivity Disorder and oxidative stress: A short term follow up study.
    Guney E; Cetin FH; Alisik M; Tunca H; Tas Torun Y; Iseri E; Isik Taner Y; Cayci B; Erel O
    Psychiatry Res; 2015 Sep; 229(1-2):310-7. PubMed ID: 26188640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the effects of pycnogenol (French maritime pine bark extract) supplementation on inflammatory biomarkers and nutritional and clinical status in traumatic brain injury patients in an intensive care unit: A randomized clinical trial protocol.
    Malekahmadi M; Moradi Moghaddam O; Islam SMS; Tanha K; Nematy M; Pahlavani N; Firouzi S; Zali MR; Norouzy A
    Trials; 2020 Feb; 21(1):162. PubMed ID: 32046747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of plant extracts tested in attention-deficit/hyperactivity disorder treatment on cell survival and energy metabolism in human neuroblastoma SH-SY5Y cells.
    Schmidt AJ; Krieg JC; Hemmeter UM; Kircher T; Schulz E; Clement HW; Heiser P
    Phytother Res; 2010 Oct; 24(10):1549-53. PubMed ID: 20878709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pycnogenol for ADHD?
    Heimann SW
    J Am Acad Child Adolesc Psychiatry; 1999 Apr; 38(4):357-8. PubMed ID: 10199105
    [No Abstract]   [Full Text] [Related]  

  • 30. The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial.
    Hirayama S; Terasawa K; Rabeler R; Hirayama T; Inoue T; Tatsumi Y; Purpura M; Jäger R
    J Hum Nutr Diet; 2014 Apr; 27 Suppl 2():284-91. PubMed ID: 23495677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pleiotropic Effects of French Maritime Pine Bark Extract to Promote Healthy Aging.
    Rohdewald P
    Rejuvenation Res; 2019 Jun; 22(3):210-217. PubMed ID: 30215292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
    Newcorn JH; Stein MA; Childress AC; Youcha S; White C; Enright G; Rubin J
    J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
    Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
    Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder.
    Bilici M; Yildirim F; Kandil S; Bekaroğlu M; Yildirmiş S; Değer O; Ulgen M; Yildiran A; Aksu H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):181-90. PubMed ID: 14687872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxidative imbalance in child and adolescent patients with attention-deficit/hyperactivity disorder.
    Ceylan M; Sener S; Bayraktar AC; Kavutcu M
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1491-4. PubMed ID: 20732373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder.
    Kahbazi M; Ghoreishi A; Rahiminejad F; Mohammadi MR; Kamalipour A; Akhondzadeh S
    Psychiatry Res; 2009 Aug; 168(3):234-7. PubMed ID: 19439364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of antioxidant therapy in children and adolescents with attention deficit hyperactivity disorder: A systematic review and network meta-analysis.
    Zhou P; Yu X; Song T; Hou X
    PLoS One; 2024; 19(3):e0296926. PubMed ID: 38547138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective effect of Pycnogenol® on ovariectomy-induced bone loss in rats.
    Mei L; Mochizuki M; Hasegawa N
    Phytother Res; 2012 Jan; 26(1):153-5. PubMed ID: 21710590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation.
    Zibadi S; Rohdewald PJ; Park D; Watson RR
    Nutr Res; 2008 May; 28(5):315-20. PubMed ID: 19083426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.